Zynerba Pharmaceuticals, Inc.(ZYNE)

Description: Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.

---

Keywords: Pharmaceutical Drugs Pain Entheogens Psychoactive Drugs Chemical Compounds Cannabidiol Osteoarthritis Epilepsy Resorcinols CBD Circulatory System Tetrahydrocannabinol Cannabinoid Neuropathic Pain Fibromyalgia Transdermal Cannabinol Fragile X Syndrome Natural Phenols Refractory Epilepsy Synthetic Cannabinoids

---

Home Page: www.zynerba.com

ZYNE Technical Analysis

80 West Lancaster Avenue
Devon, PA 19333
United States
Phone: 484 581 7505

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)